Overview
- Regencell told investors that the U.S. Department of Justice had issued a subpoena about trading in its ordinary shares, a disclosure that plaintiffs say triggered market re-pricing and prompted the lawsuit.
- The company’s SEC filing and subsequent market moves included an 18.56% one-day drop that closed at $13.56 on November 3, 2025 after the subpoena became public.
- A federal securities class action was filed alleging violations of Sections 10(b) and 20(a) and Rule 10b-5 for failing to disclose vulnerability to market manipulation and regulatory scrutiny.
- Multiple plaintiff firms are soliciting investors and institutional lead plaintiffs to move for appointment before the June 23, 2026 deadline because the Private Securities Litigation Reform Act favors large loss holders.
- The complaint highlights a stark valuation disconnect—about a $14 billion market cap despite no revenue, no approved products, roughly a dozen employees, and minimal R&D spending—which could shape damages, fiduciary reviews, and any regulatory fallout if the DOJ inquiry finds broader problems.